Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$5,171
+$131 QoQ
Shares Held
33
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,563
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026TD Capital Management LLC holds $1,134,457 across 14 Drug Manufacturers - General names. NVS ranks #11 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
3,219 | $413,641 | |
| 2 | JNJ |
Johnson & Johnson
|
1,042 | $264,636 | |
| 3 | ABBV |
AbbVie Inc.
|
784 | $197,285 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
652 | $82,373 | |
| 5 | LLY |
ELI LILLY & Co
|
66 | $79,162 | |
| 6 | PFE |
Pfizer Inc
|
1,077 | $25,934 | |
| 7 | AZN |
Astrazeneca PLC
|
113 | $21,427 | |
| 8 | AMGN |
Amgen Inc
|
53 | $19,192 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,171 | 33 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $5,040 | 33 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $4,549 | 33 | Shares | Sole | 2026-02-26 | |
| 2025-09-30 | $2,693 | 21 | Shares | Sole | 2025-11-24 | |
| 2025-06-30 | $2,541 | 21 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $2,229 | 20 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,946 | 20 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||